Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
Upcoming AWS Coverage on Regeneron Pharmaceuticals
LONDON, UK / ACCESSWIRE / April 12, 2017 / Active Wall St. blog coverage looks at the headline from Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) as the Company announced on April 11, 2017, the completion of the active recruitment phase of the Phase-2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost for the treatment of glaucoma. Register with us now for your free membership and blog access at:
http://www.activewallst.com/register/
One of Inotek Pharma's competitors within the Biotechnology space, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), is estimated to report earnings on May 04, 2017. AWS will be initiating a research report on Regeneron Pharma following the release of its next earnings results.
Today, AWS is promoting its blog coverage on ITEK; touching on REGN. Get all of our free blog coverage and more by clicking on the link below:
http://www.activewallst.com/register/
Inotek Pharma's Trabodenoson is a highly selective adenosine mimetic that lowers intraocular pressure (IOP) by augmenting the natural function of the trabecular meshwork, the primary outflow pathway in the eye. Latanoprost, a prostaglandin Analog, targets the secondary uveoscleral pathway and is the most commonly used drug for lowering IOP.
Phase-2 Fixed-dose Combination Study of Trabodenoson and Latanoprost
Inotek stated that the randomized, double-masked, Phase-2 dose-ranging trial will assess the overall benefit/risk profile of binocular topical application of different daily doses of trabodenoson (3.0% and 6.0%) when combined with latanoprost for eight weeks in patients with ocular hypertension or primary open-angle glaucoma.
During the study, three treatment combinations of trabodenoson and latanoprost will be investigated as well as two separate concentrations of latanoprost alone. The treatments are: trabodenoson 6%/latanoprost 0.005%, trabodenoson 3%/latanoprost 0.005%; trabodenoson 6%/latanoprost 0.0025%; latanoprost 0.005%; and latanoprost 0.0025%. Trabodenoson doses were selected to optimize IOP lowering, while maintaining the favorable tolerability and safety profile observed to date. Latanoprost doses were selected based on efficacy and safety profiles which vary based on dose.
The trial enrolled approximately 200 patients (original Enrollment was exceeded due to a lower than anticipated screen failure rate) with an IOP greater than or equal to 25 mmHg and less than or equal to 34 mmHg, which represents the patients most likely to receive treatment for glaucoma or ocular hypertension. Following a placebo run-in period, treatment will be administered to both eyes for a total of eight weeks.
"We have completed active recruitment of glaucoma patients in our Phase-2 FDC trial," said David P. Southwell, President and Chief Executive Officer of Inotek, "This is an important milestone as we continue to believe our FDC program has the potential to address a larger market opportunity than monotherapy and provide patients with a novel treatment option that includes two complementary eye pressure lowering mechanisms. We look forward to reporting the top-line results in July."
Meeting with FDA
Inotek also announced that the Company has secured a meeting with the US Food and Drug Administration (FDA) in the second quarter to discuss the trabodenoson monotherapy program.
"Inotek has submitted a briefing book to the FDA detailing the results of the completed MATrX-1 trial in order to seek their guidance on its continued development," said Rudolf Baumgartner, MD, Executive Vice President and Chief Medical Officer of Inotek, "We look forward to communicating the potential path forward for the monotherapy program once it is better defined."
Stock Performance
At the closing bell, on Tuesday, April 11, 2017, following the announcement, Inotek Pharma's stock jumped 5.41%, ending the trading session at $1.95. A total volume of 530.74 thousand shares were traded at the end of the day. In the last month and previous three months, shares of the Company have advanced 9.86% and 11.43%, respectively. At Tuesday's closing price, the stock's net capitalization stands at $54.05 million.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street
